Timothy P Cripe

13PUBLICATIONS
45CO-AUTHORS
Molecular targetsEthical use of new technologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 22, 2026
Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors.

|Apr 07, 2025
Clinical Trials or FDA-Approved Therapies? The Ethics of Sickle Cell Gene Therapy Access.

Timothy P Cripe, Anthony D Villella

|Jan 08, 2025
Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer.

Emily Schwarz, Himanshu Savardekar, Sara Zelinskas

|Sep 12, 2024
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy.

Wen Luo, Hai Hoang, Hongwen Zhu

|Mar 11, 2024
Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma.

Emily M Ringwalt, Mark A Currier, Andrea M Glaspell

|Jul 20, 2022
Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics.

Timothy P Cripe, Brian Hutzen, Mark A Currier

Pageof 3

Frequent Collaborators

2 joint publications

Dean Lee

2 joint publications

Mary Frances Wedekind

2 joint publications

Joseph R Stanek

2 joint publications

Emily M Ringwalt